Investors
Our Breakthrough
A New Class of Cancer Diagnostics GapScore is the first functional biomarker that directly detects endogenous single-stranded DNA (ssDNA) gaps—a newly validated, actionable vulnerability in cancer. Rather than inferring vulnerability indirectly, GapScore directly quantifies the biological defect that therapies exploit.
Market at a Glance
– $109B TAM: Global oncology diagnostics
– $6.5B SAM: Breast & ovarian cancer
– $900M SOM: BRCA-deficient tumors today with expansion into replication stress–driven cancers
Competitive Edge
Traditional Diagnostics vs GapScore:
– Indirect surrogate signals vs Direct functional
measurementIndirect surrogate signals vs Direct functional
measurement
– DSB-dependent models vs Measures ssDNA
– Static genomic snapshots vs Dynamic vulnerability
behavior
– Limited predictive power vs High therapeutic response
precision
Let’s talk
We are actively engaging seed and strategic investors to
accelerate clinical validation and commercial deployment.
Join us in launching the first clinically deployable ssDNA
gap diagnostic—unlocking a major inflection point in how
cancer is diagnosed and treated.
Interested in learning more? Contact us to request our one-pager.